These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 17497727)

  • 21. Solid-state chemistry and particle engineering with supercritical fluids in pharmaceutics.
    Pasquali I; Bettini R; Giordano F
    Eur J Pharm Sci; 2006 Mar; 27(4):299-310. PubMed ID: 16388936
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Salmeterol Xinafoate.
    Anwar MM; El-Haggar RS; Zaghary WA
    Profiles Drug Subst Excip Relat Methodol; 2015; 40():321-69. PubMed ID: 26051688
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Developing an environmentally benign process for the production of microparticles: amphiphilic crystallization.
    Murnane D; Marriott C; Martin GP
    Eur J Pharm Biopharm; 2008 May; 69(1):72-82. PubMed ID: 18082385
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Surface roughness contribution to the adhesion force distribution of salmeterol xinafoate on lactose carriers by atomic force microscopy.
    Islam N; Stewart P; Larson I; Hartley P
    J Pharm Sci; 2005 Jul; 94(7):1500-11. PubMed ID: 15924347
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparative effects of salmeterol, albuterol, and ipratropium on normal and impaired mucociliary function in sheep.
    Sabater JR; Lee TA; Abraham WM
    Chest; 2005 Nov; 128(5):3743-9. PubMed ID: 16304342
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Validation of a reverse-phase high performance liquid chromatographic method for concurrent assay of a weak base (salmeterol xinafoate) and a pharmacologically active steroid (fluticasone propionate).
    Murnane D; Martin GP; Marriott C
    J Pharm Biomed Anal; 2006 Mar; 40(5):1149-54. PubMed ID: 16280225
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Salmeterol xinafoate in children on high dose inhaled steroids.
    Russell G; Williams DA; Weller P; Price JF
    Ann Allergy Asthma Immunol; 1995 Nov; 75(5):423-8. PubMed ID: 7583864
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Surface energy changes and their relationship with the dispersibility of salmeterol xinafoate powders for inhalation after storage at high RH.
    Das S; Larson I; Young P; Stewart P
    Eur J Pharm Sci; 2009 Nov; 38(4):347-54. PubMed ID: 19732829
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comments on the Salmeterol Multicenter Asthma Research Trial.
    Seymour SM; Sullivan EJ; Chowdhury BA; Meyer RJ; Davi RC
    Chest; 2006 Sep; 130(3):930-1; author reply 931. PubMed ID: 16963702
    [No Abstract]   [Full Text] [Related]  

  • 30. Efficient cooling in supersonic jet expansions of supercritical fluids: CO and CO2.
    Christen W; Rademann K; Even U
    J Chem Phys; 2006 Nov; 125(17):174307. PubMed ID: 17100439
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol.
    Nelson HS; Weiss ST; Bleecker ER; Yancey SW; Dorinsky PM;
    Chest; 2006 Jan; 129(1):15-26. PubMed ID: 16424409
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A comparison of beclomethasone, salmeterol, and placebo in children with asthma. Canadian Beclomethasone Dipropionate-Salmeterol Xinafoate Study Group.
    Simons FE
    N Engl J Med; 1997 Dec; 337(23):1659-65. PubMed ID: 9385125
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Beta2 déjà vu.
    O'Byrne PM; Adelroth E
    Chest; 2006 Jan; 129(1):3-5. PubMed ID: 16424402
    [No Abstract]   [Full Text] [Related]  

  • 34. Aerodynamic deposition of combination dry powder inhaler formulations in vitro: a comparison of three impactors.
    Taki M; Marriott C; Zeng XM; Martin GP
    Int J Pharm; 2010 Mar; 388(1-2):40-51. PubMed ID: 20026261
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of the short-term effects of salmeterol and formoterol on heart rate variability in adult asthmatic patients.
    Eryonucu B; Uzun K; Güler N; Tuncer M; Sezgi C
    Chest; 2005 Sep; 128(3):1136-9. PubMed ID: 16162698
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Differentiating asthma and COPD patients.
    El-Kassimi FA
    Chest; 2004 Aug; 126(2):653-4; author reply 654-5. PubMed ID: 15302761
    [No Abstract]   [Full Text] [Related]  

  • 37. Performance of large- and small-volume valved holding chambers with a new combination long-term bronchodilator/anti-inflammatory formulation delivered by pressurized metered dose inhaler.
    Nagel MW; Wiersema KJ; Bates SL; Mitchell JP
    J Aerosol Med; 2002; 15(4):427-33. PubMed ID: 12581509
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of montelukast and salmeterol on physical performance and exercise economy in adult asthmatics with exercise-induced bronchoconstriction.
    Steinshamn S; Sandsund M; Sue-Chu M; Bjermer L
    Chest; 2004 Oct; 126(4):1154-60. PubMed ID: 15486377
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The effect of ionic strength on liposome-buffer and 1-octanol-buffer distribution coefficients.
    Austin RP; Barton P; Davis AM; Manners CN; Stansfield MC
    J Pharm Sci; 1998 May; 87(5):599-607. PubMed ID: 9572911
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of fluticasone propionate/salmeterol on lung hyperinflation and exercise endurance in COPD.
    O'Donnell DE; Sciurba F; Celli B; Mahler DA; Webb KA; Kalberg CJ; Knobil K
    Chest; 2006 Sep; 130(3):647-56. PubMed ID: 16963658
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.